NASDAQ:NYMX

Nymox Pharmaceutical - NYMX Stock Forecast, Price & News

$0.41

+0.05 (+13.71%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.37
▼
$0.42
50-Day Range: $0.33
▼
$0.61
52-Week Range: $0.19
▼
$2.15

Volume: 79,792 shs
Average Volume: 74,692 shs
Market Capitalization: $37.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Nymox Pharmaceutical (NASDAQ:NYMX) Stock

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.

Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

NYMX Stock News Headlines

September 27, 2022 | finance.yahoo.com

A Nymox Pharmaceutical Corporation (NASDAQ:NYMX) insider increased their holdings by 32% last year

September 27, 2022 | americanbankingnews.com

Nymox Pharmaceutical (NASDAQ:NYMX) Research Coverage Started at StockNews.com

August 17, 2022 | nasdaq.com

We Think Nymox Pharmaceutical (NASDAQ:NYMX) Needs To Drive Business Growth Carefully

July 15, 2022 | msn.com

U.S. shares higher at close of trade; Dow Jones Industrial Average up 2.15%

July 15, 2022 | finance.yahoo.com

NYMOX Updates Shareholders

July 14, 2022 | finance.yahoo.com

NYMOX Receives Deficiency Letter from NASDAQ

May 23, 2022 | marketwatch.com

Nymox Pharmaceutical Down 64% on FDA Refusal to File Letter

May 23, 2022 | seekingalpha.com

NYMOX down 46% on Refuse to File letter from FDA for fexapotide for enlarged prostate

May 23, 2022 | marketwatch.com

Nymox Application for Fexapotide Triflutate Rejected by FDA >NYMX

May 23, 2022 | benzinga.com

Why Nymox Pharma Shares Sinking to 52-Week Low?

May 9, 2022 | uk.investing.com

Executives Buy Around $5M Of 4 Penny Stocks

May 6, 2022 | nasdaq.com

Friday 5/6 Insider Buying Report: ALGN, NYMX

April 4, 2022 | finance.yahoo.com

Nymox Announces Closing of $6.4 Million Financing

April 3, 2022 | finance.yahoo.com

A Nymox Pharmaceutical Corporation (NASDAQ:NYMX) insider increased their holdings by 1.1% last year

March 18, 2022 | msn.com

Here's Why Nymox Pharmaceuticals Shares Are Moving

March 18, 2022 | baystreet.ca

Nymox Direct Offering

March 18, 2022 | seekingalpha.com

Nymox Pharmaceutical announces $5M registered direct offering

March 18, 2022 | finance.yahoo.com

Nymox Announces $5 Million Registered Direct Offering

March 3, 2022 | marketwatch.com

Nymox Seeks FDA OK for Enlarged Prostate Treatment >NYMX

March 3, 2022 | seekingalpha.com

Nymox stock rises 8% as it files for FDA approval of drug treating enlarged prostate

March 3, 2022 | finance.yahoo.com

NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate

January 3, 2022 | nasdaq.com

Insiders at Nymox Pharmaceutical Corporation (NASDAQ:NYMX) recouped some losses this week after buying this year, still down US$31k

December 31, 2021 | nasdaq.com

Nymox Pharmaceutical Corp Shares Near 52-Week Low - Market Mover

December 13, 2021 | finance.yahoo.com

Nymox Shareholder Update

November 15, 2021 | finance.yahoo.com

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

NYMX Company Calendar

Last Earnings: 8/15/2022
Today: 10/01/2022
Next Earnings (Estimated): 11/11/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NYMX
CUSIP: N/A
CIK: 1018735
Web: www.nymox.com
Phone: (800) 936-9669
Fax: 514-332-2227
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,540,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -2,053.99%
Return on Assets: -358.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.91
Quick Ratio: 1.90

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.01) per share
Price / Book: -41.47

Miscellaneous

Outstanding Shares: 90,280,000
Free Float: 41,529,000
Market Cap: $37.44 million
Optionable: Optionable
Beta: 0.81

Key Executives

Dr. Paul Averback DABP (Age 71)
M.D., Founder, Chairman, CEO & Pres
Comp: $750k

Mr. Randall J. Lanham Esq. (Age 58)
J.D., Gen. Counsel, Sec., COO & Director
Comp: $435.29k

Ms. Lin Dodd
QA and Compliance Mang.

Key Competitors

View All Competitors

Insiders & Institutions

James George Robinson
Bought 1,151,515 shares on 5/2/2022
Total: $1.90 M ($1.65/share)

View All Insider Transactions
View All Institutional Transactions

NYMX Stock - Frequently Asked Questions

How have NYMX shares performed in 2022?: Nymox Pharmaceutical's stock was trading at $1.30 at the beginning of the year. Since then, NYMX stock has decreased by 68.1% and is now trading at $0.4147.
View the best growth stocks for 2022 here.
When is Nymox Pharmaceutical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our NYMX earnings forecast.
How were Nymox Pharmaceutical's earnings last quarter?: Nymox Pharmaceutical Co. (NASDAQ:NYMX) posted its earnings results on Monday, August, 15th. The biopharmaceutical company reported $0.01 EPS for the quarter.
What other stocks do shareholders of Nymox Pharmaceutical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC).

What is Nymox Pharmaceutical's stock symbol?: Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."
How do I buy shares of Nymox Pharmaceutical?: Shares of NYMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Nymox Pharmaceutical's stock price today?: One share of NYMX stock can currently be purchased for approximately $0.41.
How much money does Nymox Pharmaceutical make?: Nymox Pharmaceutical (NASDAQ:NYMX) has a market capitalization of $37.44 million. The biopharmaceutical company earns $-12,540,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.
How can I contact Nymox Pharmaceutical?: Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The official website for the company is www.nymox.com. The biopharmaceutical company can be reached via phone at (800) 936-9669, via email at info@nymox.com, or via fax at 514-332-2227.

This page (NASDAQ:NYMX) was last updated on 10/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms